Analysis of the Effect of Rituximab Combined with CHOP Regimen in the Treatment of Aggressive B-cell Lymphoma

Objective To summarize and analyze the application effect of rituximab combined with CHOP regimen in the treatment of aggressive B-cell lymphoma. Methods 90 patients with aggressive B-cell lymphoma admitted in our hospital from January,2008 to November, 2013 were divided into the control group(45 cases), treated by CHOP regimen and the observation group(45cases), treated by rituximab combined with CHOP regimen. The clinical efficacy and adverse reactions of two groups were compared. Results After treatment, the total efficiency of the observation group was 82.22%, significantly higher than that(62.22%) of the control group, the difference was statistically significant(P0.05). Major adverse reactions of two groups were mild or moderate myelosuppression and gastrointestinal reactions, mild transaminase elevation and constipation. The incidence of adverse reactions of the observation group was 31.11%, which was higher than that(28.89%) of the control group, but with no statistically significant difference(P0.05). Conclusion Compared with the CHOP regimen alone, the rituximab combined with CHOP regimen in the treatment of aggressive B-cell lymphoma has better efficacy without increasing the side effects, which can be used as the first-line treatment regimen.